IN8bio Reports Inducement Grant Under Nasdaq Listing Rule

Biotech company announces new stock options for employees

Apr. 4, 2026 at 3:27am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of stock certificates and a metal pen, symbolizing corporate finance and strategy.A stock option grant signals IN8bio's commitment to building a strong, talented team as it advances its cancer therapy pipeline.NYC Today

IN8bio, Inc., a Nasdaq-listed biotech company, has reported granting new stock options to employees as an inducement to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters

Inducement grants are a common practice for publicly traded companies to attract and retain top talent, especially in competitive industries like biotech. These grants provide employees with a financial incentive to join and stay with the company.

The details

The company announced it has granted stock options to purchase up to an aggregate of 75,000 shares of the company's common stock to four new employees. The options have an exercise price of $12.50 per share, which was the closing price of the company's common stock on the grant date. The options will vest over a four-year period, with 25% vesting on the one-year anniversary of the employee's start date and the remaining 75% vesting in equal monthly installments over the following 36 months.

  • The options were granted on April 3, 2026.

The players

IN8bio, Inc.

A Nasdaq-listed biotech company that develops novel therapies for cancer treatment.

Got photos? Submit your photos here. ›

The takeaway

This inducement grant demonstrates IN8bio's commitment to building a strong team of talented employees as it continues to advance its pipeline of cancer therapies. These types of grants are common practice for publicly traded companies to attract top talent in competitive industries.